JAZETA 100 MG TBL FLM 28

What is the maximum co-payment for JAZETA?

If the insurance company contributes, the maximum co-payment is 635,68 Kč. The maximum pharmacy price is 878,43 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.

Does the medicine have reimbursement from public health insurance?

Yes, but the reimbursement conditions (reporting limit) have not been set.

Does JAZETA have a counted co-payment set?

No, this medicine has no counted co-payment.

How much does the insurance company pay for one dispensed reimbursed pack?

242,75 Kč.

Does the insurance company pay a higher amount in some cases?

No, the medicine has no increased reimbursement.

Does the medicine have an indication restriction?

Sitagliptin je hrazen v kombinaci s metforminem a/nebo sulfonylureou nebo v kombinaci s thiazolidindiony u pacientů, u nichž použití maximálních tolerovaných dávek zmíněných léčiv po dobu alespoň 3 měsíců společně s režimovými opatřeními nevedlo k uspokojivé kompenzaci diabetu definované jako hladina HbA1c nižší než 53 mmol/mol. Nedojde-li k prokazatelnému zlepšení kompenzace diabetu o 7 % či vyššímu poklesu hladiny HbA1c při kontrole po 6 měsících léčby, sitagliptin není dále hrazen. V kombinaci s inzulinem nejsou léčivé přípravky s obsahem sitagliptinu hrazeny.

Is it available without a medical prescription?

No, the medicine cannot be obtained without a prescription.

Which medical specialist may prescribe JAZETA?

Prescription is not conditional on a medical specialization.

What is the composition of JAZETA?

Monohydrát sitagliptin-hydrochloridu (113,376 mg), sitagliptin (100 mg), hydrogenfosforečnan vápenatý, neznámá látka s kódem 3755, sodná sůl kroskarmelosy, neznámá látka s kódem 4174, magnesium-stearát, polyvinylalkohol, oxid titaničitý, makrogol 3350, ointmentek, žlutý oxid železitý, červený oxid železitý. More information about the composition can be found in the SPC, section 6.1.

Where can I find information about correct use of the medicine?

Which medicines are similar to JAZETA?

The medicine belongs to ATC group A10BH01 – SITAGLIPTIN. Medicines with the same active substance can be found here.

Who manufactures JAZETA?

VIATRIS LIMITED, Dublin (IRL)

Is the medicine in shortage?

The latest report from the manufacturer is from 27. 3. 2025. Production was terminated with effect from 27. 3. 2025. The manufacturer lists medicines with the following code as a potential substitute: